Monday, March 27, 2023, Tampa, Florida, 11:45 AM – 1:15 PM Eastern Time

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Endometrial Cancer

Part 2 of a 2-Part CME Symposium Series Held in Conjunction with the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer®

Location
Tampa Convention Center
333 S Franklin Street
Tampa, FL 33602
Phone: (813) 274-8511

Program Schedule — Eastern Time
11:15 AM – 11:45 AM — Registration and Lunch
11:45 AM – 1:15 PM — Educational Meeting

Meeting Room
Ballroom B – Level 1


This event will also be webcast live.
Please see Registration tab for details.
There is no fee to participate in this event. For the in-person symposium in Tampa, preregistration is required as seating is limited.  
 
Faculty
Robert L Coleman, MD
Chief Medical Officer
Sarah Cannon Research Institute (SCRI)
Gynecologic Oncology
The Woodlands, Texas

Matthew A Powell, MD
Professor
Department of Obstetrics and Gynecology
Washington University School of Medicine
St Louis, Missouri


Brian M Slomovitz, MD
Professor, OB-GYN
Florida International University
Director, Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinai Medical Center
Miami, Florida

Moderator
Shannon N Westin, MD, MPH
Professor
Director, Early Drug Development
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.
Program Schedule — Eastern Time
11:15 AM – 11:45 AM — Registration and Lunch Buffet
11:45 AM – 1:15 PM — Educational Meeting

MODULE 1: Immune Checkpoint Inhibitors for Patients with Advanced Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Endometrial Cancer — Dr Powell

  • Current indications for MSI/MMR testing in patients with endometrial cancer; available testing platforms
  • Key efficacy and safety data with dostarlimab for patients with advanced or recurrent MSI-H/dMMR tumors in the GARNET trial
  • Efficacy and safety findings with pembrolizumab monotherapy for the cohort of patients with previously treated MSI-H/ dMMR advanced endometrial cancer in the KEYNOTE-158 study
  • Current clinical roles for dostarlimab and pembrolizumab monotherapy in the treatment of MSI-H/dMMR advanced endometrial cancer; optimal integration into practice
  • Available clinical trial data with other anti-PD-1/PD-L1 antibodies (eg, durvalumab, atezolizumab) for patients with MSI-H/dMMR endometrial cancer
  • Antitumor efficacy observed with pembrolizumab/lenvatinib among patients with MSI-H/dMMR endometrial cancer in the KEYNOTE-775 trial; current nonresearch role, if any
  • Emerging positive results from the Phase III RUBY and NRG-GY018 studies evaluating dostarlimab and pembrolizumab, respectively, in combination with chemotherapy for advanced or recurrent endometrial cancer; potential implications for the management of MSI-H/dMMR disease

MODULE 2: Immunotherapy-Based Strategies for Patients with MMR-Proficient (pMMR) Endometrial Cancer — Dr Coleman

  • Biologic rationale for combining immune checkpoint inhibitors with VEGF inhibitors for pMMR endometrial cancer
  • Key efficacy and safety data with pembrolizumab in combination with lenvatinib for patients with previously treated advanced pMMR tumors in the KEYNOTE-775 trial
  • Antitumor efficacy observed with pembrolizumab/lenvatinib in patients with MSI-H/dMMR endometrial cancer in the KEYNOTE-775 trial; current nonresearch role, if any
  • Design, eligibility criteria and key efficacy and safety endpoints for the Phase III LEAP-001 trial comparing pembrolizumab/lenvatinib to chemotherapy as first-line treatment for advanced or recurrent endometrial cancer; estimated completion date
  • Response rates observed with single-agent dostarlimab among patients with recurrent and/or advanced pMMR disease in the GARNET trial
  • Potential ramifications of the emerging positive results from the RUBY and NRG-GY018 trials for the management of pMMR endometrial cancer

MODULE 3: Diagnosis and Management of Adverse Events Associated with Immune Checkpoint Inhibitors Alone and in Combination for Endometrial Cancer — Dr Westin

  • Incidence, severity and timing of toxicities associated with pembrolizumab/lenvatinib in patients with endometrial cancer
  • Appropriate initial dosing and dose-modification strategies with pembrolizumab/lenvatinib; available data exploring the effects of lenvatinib dose reduction on antitumor activity
  • Similarities and differences in the frequency and type of adverse events associated with pembrolizumab and dostarlimab monotherapy
  • Appropriate monitoring for and management of immune-mediated toxicities and other adverse events with pembrolizumab or dostarlimab
  • Emerging safety information from the RUBY and NRG-GY018 studies; potential implications of concomitant delivery of anti-PD-1/PD-L1 antibodies and chemotherapy for adverse event monitoring and management
  • Role of rechallenge for patients for whom anti-PD-1/PD-L1 antibody therapy has been held as a result of immune-related adverse events

MODULE 4: Novel Investigational Agents and Strategies Under Evaluation for Patients with Endometrial Cancer — Dr Slomovitz

  • Mechanism of action of selinexor and biologic rationale for targeting XPO1 in patients with endometrial cancer
  • Key efficacy and safety findings from the Phase III SIENDO trial evaluating selinexor as maintenance therapy after first-line chemotherapy for patients with advanced endometrial cancer
  • Efficacy of selinexor in patients with p53 wild-type disease and potential role of this agent as up-front maintenance therapy
  • Biologic rationale for, early-phase data with and ongoing evaluation of PARP inhibitors for endometrial cancer
  • Design, eligibility criteria and key endpoints of the Phase III DUO-E study of durvalumab and platinum-based chemotherapy followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer; estimated completion date
  • Early antitumor activity observed with HER2-targeted therapies for HER2-positive endometrial cancer (eg, trastuzumab, trastuzumab/pertuzumab, trastuzumab deruxtecan)
  • Other novel agents and strategies under evaluation for the treatment of advanced endometrial cancer

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate the importance of microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiency assessment for patients with endometrial cancer, and adapt current testing practices to optimally identify genetic abnormalities.
  • Review the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or MMR-deficient endometrial cancer, and appropriately integrate these agents into the care of patients.
  • Recognize the biologic rationale for and available data with the combination of anti-PD-1/PD-L1 antibodies with agents targeting the VEGF pathway, and select patients with metastatic endometrial cancer for this novel approach.
  • Design and implement a plan of care to manage side effects and toxicities associated with immune checkpoint inhibitor-based therapies for endometrial cancer in order to support quality of life and continuation of treatment.
  • Describe the scientific justification for, published research data with and toxicity profiles of novel agents and strategies under investigation for endometrial cancer, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Coleman — Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Merck, Myriad Genetic Laboratories Inc, Seagen Inc; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Merck, Seagen Inc; Data and Safety Monitoring Board/Committee: Eisai Inc. Dr Powell — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, Merck, Roche Laboratories Inc, Seagen Inc; Contracted Research: GSK. Dr Slomovitz — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, EQRx, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Incyte Corporation, Lilly, Merck, Novartis, Seagen Inc.

MODERATOR — Shannon N Westin, MD, MPH – Consulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, EQRx, Genentech, a member of the Roche Group, GSK, ImmunoGen Inc, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, NGM Bio, Nuvectis Pharma Inc, Seagen Inc, Vincerx Pharma, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bio-Path Holdings, Clovis Oncology, Genentech, a member of the Roche Group, GSK, Mereo BioPharma, OncXerna Therapeutics Inc, Zentalis Pharmaceuticals.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, and Karyopharm Therapeutics.

Tampa Convention Center
333 S Franklin Street
Tampa, FL 33602
Phone: (813) 274-8511

Meeting Room
Ballroom B – Level 1

Directions
The Tampa Convention Center is the main venue for the SGO Annual Meeting on Women’s Cancer.

 
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of endometrial cancer.

​ ​ ​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 11:15 AM ET on Monday, March 27th. If you are interested in attending, please visit our registration desk located at the Tampa Convention Center – Ballroom B ( Level 1).

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Notice To Attendees:
  • Please note, onsite registration does not guarantee seating and participation in meal service. We will accommodate onsite attendees on a first come first served basis.
  • Registration for this event is independent of registration for the 2023 SGO Annual Meeting.

LIVE WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.